Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Share-based Compensation (2017 - 2025)

IGC Pharma (IGC) has disclosed Share-based Compensation for 15 consecutive years, with -$3.5 million as the latest value for Q3 2025.

  • Quarterly Share-based Compensation fell 975.12% to -$3.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Sep 2025, up 20.84% year-over-year, with the annual reading at $1.6 million for FY2025, 7.5% down from the prior year.
  • Share-based Compensation for Q3 2025 was -$3.5 million at IGC Pharma, down from $4.7 million in the prior quarter.
  • The five-year high for Share-based Compensation was $4.7 million in Q2 2025, with the low at -$3.5 million in Q3 2025.
  • Average Share-based Compensation over 5 years is $514210.5, with a median of $455000.0 recorded in 2025.
  • Peak annual rise in Share-based Compensation hit 1069.15% in 2025, while the deepest fall reached 975.12% in 2025.
  • Over 5 years, Share-based Compensation stood at $523000.0 in 2021, then fell by 7.46% to $484000.0 in 2022, then increased by 8.68% to $526000.0 in 2023, then fell by 27.57% to $381000.0 in 2024, then tumbled by 1023.36% to -$3.5 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at -$3.5 million, $4.7 million, and $455000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.